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Purpose: To assess the incidence and evolution of biliary alterations adjacent to the ablation 
area in patients with hepatic malignancies during the first 3 months after percutaneous 
irreversible electroporation (IRE) and to investigate associated changes in laboratory values.
Material and Methods: Bile ducts located within a ≤1.0 cm radius of the ablation zone 
were analyzed in 45 patients by preinterventional and postinterventional MRI (1–3 days, 6 
weeks, and 3 months after IRE). Moreover, levels of alkaline phosphatase (AP) and serum 
bilirubin (SB) were examined for evidence of bile duct injury. Biliary alterations and the 
presence of postinterventional-elevated laboratory levels were correlated with features of the 
lesions, patients, ablation procedures, and laboratory values.
Results: A total of 80 bile ducts were located within a 1.0 cm radius of the ablation zone: 59 
were encased, 16 were abutting and 5 were located within a radius of 0.1–1.0 cm of the 
ablation area. In total, 38 biliary injuries (narrowing, n=22; dilatation, n=14; biloma, n=2) 
were detected, 3 cases of narrowing occurred for the first time 6 weeks and 3 months after 
IRE, 21 alterations (dilatation: n=9; narrowing; n=10; biloma: n=2) had resolved during the 
first 6 weeks, 1 alteration (dilatation: n=1) had resolved by the last follow-up control. Three 
months after IRE, 19 patients showed elevated levels of AP, whereas SB levels were 
increased in 10 cases. No significant association between biliary alterations or postinterven-
tional-elevated laboratory values and the investigated characteristics of lesions, patients, 
ablation procedures or laboratory values could be proven.
Conclusion: Different alterations of bile ducts adjacent to an IRE ablation zone are 
common, of which dilatation and especially narrowing commonly represent a long-term 
complication after IRE. Moreover, a definite correlation between the frequently observed 
prolonged post-ablative elevation of AP- and SB-levels and the postinterventional biliary 
alterations could not be proven.
Keywords: bile ducts, hepatic tumors, electroporation
Introduction
Despite the continuing evolution of ablation technology, the treatment of hepatic 
tumors in critical locations such as those adjacent to certain intrahepatic structures 
(eg, bile ducts) still represents a challenge in local ablation therapy. Because 
percutaneous thermal ablation techniques such as radiofrequency ablation (RFA) 
are contraindicated for hepatic tumors in proximity to bile ducts because of the risk 
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of thermal damage,1 the role of irreversible electroporation 
(IRE) has constantly increased during the last few years.
Causing cell death through the repeated application of 
high-voltage electrical impulses, which create irreversible 
damage to the membranes of tumor cells,2 IRE, as 
a predominantly nonthermal ablative method, represents 
a viable alternative to thermal ablations. IRE also affects 
bile ducts but does not damage their architectural integrity.3 
As a safe method for the ablation hepatic tumors adjacent to 
major bile ducts,4 at this point of time little is known about 
the alterations of bile ducts in proximity to an IRE ablation 
area. In particular, hardly any information is available in the 
current literature about the evolution of these alterations.
The aim of the present study was to evaluate the 
occurrence and the evolution of alterations in bile ducts 
located in proximity to the IRE ablation zone in patients 
with hepatic malignancies during the first 3 months after 
IRE. Moreover, the objective was to determine any poten-
tial risk factors associated with detected biliary complica-
tions and to analyze a potential correlation between biliary 
alterations and levels of alkaline phosphatase and serum 
bilirubin measured before and during the first 3 months 
after the intervention.
Materials and Methods
Study Design, Participant Selection and 
Patient Characteristics
To investigate alterations in bile ducts adjacent to the abla-
tion area after percutaneous IRE of malignant liver tumors, 
MRI images of all ablations performed at University 
Hospital Regensburg between December 2011 and 
May 2018 were retrospectively evaluated. The single- 
center retrospective observational study was approved by 
the local ethics committee (Ethics Committee of the 
University of Regensburg approval number 18-1027-104) 
and followed the guidelines outlined in the Declaration of 
Helsinki. Each patient provided written informed consent 
for the acquisition of contrast-enhanced MR images, the 
ablation procedure, and the anonymous use of the data for 
scientific purposes. The following inclusion criteria were 
applied to participate in the study: (I) Primary or secondary 
liver malignancies. (II) Liver tumors treated by percuta-
neous IRE. (III) Examination by contrast-enhanced MR 
images of the entire liver, including the hepatobiliary 
phase, before the intervention and at three defined moments 
in time after IRE. These three moments were 1–3 days, 6 
weeks, and 3 months after the ablation. (IV) Bile ducts were 
located within a 1.0 cm radius of the ablation area, mea-
sured from the edge of the ablation zone at the follow-up 
MR imaging examination 1–3 days after the intervention. 
The location of the bile ducts in relation to the ablation zone 
was divided into three classifications: encased, that is, com-
pletely surrounded by the ablation zone; abutting, that is, 
directly adjacent to the ablation zone, but not encased; and 
distant, that is, 0.1–1.0 cm from the ablation zone. A prior 
treatment of liver malignancies by any other kind of therapy 
(eg, surgery, systemic chemotherapy) was not an exclusion 
criterion.
Forty-five patients (34 men and 11 women) aged 68.3 
± 11.6 years who had undergone IRE ablations of 62 
hepatic lesions in 53 ablation procedures fulfilled the men-
tioned conditions and were included in the study (Table 1). 
The mean tumor diameter was 2.0 cm ± 1.1 (range, 
0.4–4.4 cm). Thirty-four of 62 lesions (in 27 patients) 
were primary liver tumors, 28 of 62 lesions (in 18 patients) 
were secondary liver tumors (Table 2). In 45 sessions only 
one tumor was ablated, in seven sessions the ablation of 
two tumors was performed, and in one session three 
tumors were ablated, all at once.
The pre- and postinterventional MR images were ana-
lyzed by two radiologists with 4 years and 7 years of 
Table 1 Baseline Patient and Disease Characteristics
Characteristics
Age (y)






Mean ± SD 2.0 ± 1.1
Range 0.4–4.4
Patients with liver cirrhosis, n (%) 16 (35.6)
Tumor localization, n (%)
Segment I 2 (3.2)
Segment II 6 (9.7)
Segment III 3 (4.8)
Segment IVa 7 (11.3)
Segment IVb 8 (12.9)
Segment V 13 (21.0)
Segment VI 7 (11.3)
Segment VII 2 (3.2)
Segment VIII 14 (22.6)
Abbreviation: SD, standard deviation.
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experience in abdominal imaging. Each MR image was 
examined for possible biliary alterations, concentrating on 
dilatation and narrowing of the bile ducts. Moreover, the 
occurrence of bilomas was observed and noted, as they 
were considered to be a postablative complication. During 
several follow-up controls, the evolution of biliary alterations 
was evaluated. Each detected biliary alteration was categor-
ized based on the Common Terminology Criteria for Adverse 
Events (CTCAE), Version 5.0.5 All MR scans contained the 
whole liver and were conducted with a hepatocyte-specific 
contrast agent (gadolinium ethoxybenzyl diethylenetriamine 
pentaacetic acid; Primovist; Bayer Schering, Berlin, 
Germany). The MR protocol included the following 
sequences: T2 haste, T1 vibe3d in-phase, T1 vibe3d out-of- 
phase, T1 vibe3d fat-suppressed, T1 vibe3d fat-suppressed 
contrast-enhanced early arterial phase, T1 vibe3d fat- 
suppressed contrast-enhanced late arterial phase, T1 vibe3d 
fat-suppressed contrast-enhanced portal venous phase, T2 
blade fat-suppressed contrast-enhanced, diffusion trace con-
trast-enhanced, T1 vibe3d fat-suppressed delayed phase.
Levels of alkaline phosphatase and serum bilirubin, 
measured at each of the follow-up controls, were com-
pared with the preinterventional levels, because elevated 
alkaline phosphatase or bilirubin levels could correlate 
with bile duct alterations. Because of the biological varia-
tion of laboratory values, increases in alkaline phosphatase 
≥117 U/L or in serum bilirubin ≥1.0 mg/dL were consid-
ered clinically significant and abnormal.
Irreversible Electroporation (IRE)
All IRE were performed percutaneously with deep muscle 
relaxation using the NanoNife system (AngioDynamics, 
Latham, New York). The operator used two to six mono-
polar 18-gauge IRE probes. They were placed around the 
target tumor. If the distance between two probes was more 
than 2.0 cm because of the tumor size, one additional 
probe was placed in the center of the tumor. After that, 
the pulses were applied consecutively between the probes. 
The IRE parameters were as follows: pulses per cycle, 70; 
pulse length, 90 µs; electric field, 1500 V/cm needle dis-
tance. A test pulse of 270 V was delivered before the 
delivery of the 90 therapeutic pulses to confirm sufficient 
conductivity.
Statistical Analysis
All collected data are presented as frequency counts and 
percentages. To identify variables for prediction of biliary 
changes and the postinterventional elevation of laboratory 
values at the specific follow-up points, a binary logistic 
regression model was used. Equal correlation of the binary 
response for individual patients was assumed, implying an 
exchangeable correlation structure. As effect estimates, 
maximum-likelihood odds-ratio estimators and 95% con-
fidence intervals are presented. A p-value of ≤0.05 was 
considered statistically significant. All statistical analyses 
were performed with SPSS statistic (IBM SPSS Statistics, 
version 25). The analyzed variables for the prediction of 
biliary alterations were postinterventional presence of ele-
vated levels of alkaline phosphatase and serum bilirubin, 
age (<65y vs ≥65y), sex, nature of the bile duct adjacent to 
the ablation zone (minor vs major), the presence of liver 
cirrhosis, number of IRE electrodes (≤4 vs >4), localiza-
tion of the bile duct with regard to the ablation zone 
(abutting/distant vs encased), tumor type (primary vs sec-
ondary hepatic malignancy), ablation volume (≤60 mL vs 
>60 mL), the presence of hepatic stents or metallic 
implants and the relative distance from needle to bile 
duct (≤0.3 cm vs >0.3 cm). Moreover, the potential influ-
ence of the ablation volume (≤60 mL vs >60 mL) and the 
tumor volume (≤1.8 mL vs >1.8 mL) on the postinterven-
tional elevation of alkaline phosphatase or serum bilirubin 
was evaluated.
Results
In the current study, 80 bile ducts in 45 patients were 
located within a 1.0 cm radius of the ablation zone. Fifty- 
nine (73.8%) of the 80 bile ducts were encased by the 
ablation defect. Sixteen (20.0%) abutted the ablation 
defect and 5 (6.2%) were located within a radius of 
0.1–1.0 cm of the ablation area. During the first 3 months 
Table 2 Tumor Types of 45 Patients Treated by Irreversible 
Electroporation of Malignant Liver Tumors








Colorectal tumor 12 20
Mammarian carcinoma 3 5
Others* 3 3
Total 45 62
Notes: *Carcinoma of unknown origin, choroidal melanoma, pancreatic 
adenocarcinoma. 
Abbreviations: HCC, hepatocellular carcinoma; CCC, cholangiocellular 
carcinoma.
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after IRE, alterations were observed in 38 (47.5%; 19 
patients) of the 80 bile ducts. An overview of the different 
types and the development of biliary alterations is pre-
sented in Table 3. Narrowing of the bile duct (n=22; 
57.9%) was the most frequently observed alteration, fol-
lowed by dilatation of the bile duct (n=14; 36.8%) and 
biloma (n=2; 5.3%). Details about the type of bile duct and 
alterations are illustrated in Table 4. Alterations of major 
bile ducts were detected in 4 of 12 cases (33.3%), whereas 
alterations of minor bile ducts were observed in 34 of 68 
cases (50.0%). All detected biliary alterations were cate-
gorized “grade 1” based on CTCAE Version 5.0. In the 
binary logistic regression model, no significant risk factors 
for the occurrence of biliary alteration or postinterven-
tional elevated laboratory values were detected (Tables 5 
and 6).
Early Alterations
Alterations were observed in 32 of the 80 (40.0%) bile 
ducts 1–3 days after IRE. Fourteen of the 32 altered bile 
ducts were dilatated (36.8%), 16 were narrowed (42.1%) 
and 2 bilomas (5.3%) were noted (Table 3). In one case of 
bile duct narrowing, a simultaneous cholestasis was 
observed at the first follow-up control but had completely 
resolved after 6 weeks.
Delayed Alterations
Three (7.9%) of the 38 biliary alterations (narrowing: n=3) 
were noted for the first time 6 weeks after the intervention, 
whereas 3 (7.9%) alterations (narrowing: n=3) occurred 
for the first time 3 months after IRE.
Evolution of Alterations
A total of 21 alterations (dilatation: n=9; narrowing; n=10; 
biloma: n=2) had resolved during the first 6 weeks. The 
detected bilomas (n=2) had resolved during the first 6 
weeks after the intervention without any additional treat-
ment such as abdominal draining. One bile duct dilatation 
showed spontaneous regression 3 months after the 
intervention.
Laboratory Values
An overview of the evolution of alkaline phosphatase and 
serum bilirubin levels after IRE in 53 ablation procedures 
is presented in Table 7. During the first 3 days after IRE, 
biliary alterations with simultaneous elevation of alkaline 
phosphatase levels were detected in seven cases (13.2%) 
of all 53 ablation procedures, of which elevated alkaline 
phosphatase levels were pre-existent before IRE in 5 cases 
(9.4%). Increased levels of serum bilirubin associated with 
biliary complications were noted in 12 cases (22.6%), of 
Table 3 Number and Types of Biliary Alterations During the First 3 Months After IRE
Day 1–3 6 Weeks 3 Months Alterations (Total)
Alterations Alterations Alterations
Number Number New Resolved Number New Resolved
Dilatation 14 5 0 9 4 0 1 14
Narrowing 16 9 3 10 12 3 0 22
Biloma 2 0 0 2 0 0 0 2
38
Abbreviation: IRE, irreversible electroporation.
Table 4 Types and Numbers of Bile Ducts Adjacent to the Ablation Zone and Number of Bile Ducts with Alterations with Regard to 
Their Localization
Bile Duct Total Number of Bile Ducts/Number of Bile 
Ducts with Alterations
Number of Bile Ducts Adjacent to the Ablation Zone/ 





Within a Radius of 
0.1–1.0 cm/Altered
Major bile ducts 12/4 4/1 6/2 2/1
Minor bile ducts 68/34 55/28 10/5 3/1
Total 80/38 59/29 16/7 5/2
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which 3 (5.7%) had already been observed before the 
intervention. Six weeks after the intervention, the number 
of cases of abnormal levels of alkaline phosphatase and 
serum bilirubin decreased from 7 to 4 (7.5%) and 12 to 3 
(5.7%), respectively. Three months after IRE, biliary 
alterations associated with elevated levels of alkaline 
phosphatase and serum bilirubin were observed in two 
cases (3.8%) and 2 cases (3.8%), respectively. During the 
6-week and the 3-month follow-up control, no newly 
elevated levels of alkaline phosphatase or serum bilirubin 
were noted in patients with biliary alterations. In the 
current study, postinterventional elevated levels of alkaline 
phosphatase (p= 0.978; OR= 0.98; 95% CI: 0.25–3.78) or 
serum bilirubin (p= 0.943; OR= 0.99; 95% CI: 0.31–3.12) 
did not significantly occur more frequently in patients 
suffering from post-IRE bile duct injuries.
Discussion
If surgical resection is impossible because the patient 
suffers from several comorbidities6 or because of the cri-
tical tumor localization, ablative methods such as IRE play 
an important role in the therapy of primary or secondary 
hepatic malignancies. In particular, IRE has become 
a viable alternative for the therapy of peribiliary tumors 
during the last few years because of its predominantly 
nonthermal mode of action.
Recently, several studies have investigated biliary altera-
tions and changes in laboratory values after hepatic IRE. In 
animal studies conducted by Rubinsky et al and Lee et al, the 
architecture of bile ducts remained undamaged, although 
mild histopathologic changes, eg, wall necrosis and perido-
chal edema, were observed.3,7 In contrast, Distelmaier et al, 
who observed their study population for 2 years after IRE of 
hepatic malignancies, described a temporary, mild to moder-
ate cholestasis in 5 (23.8%) of 21 patients 2–6 weeks after the 
intervention. No further cholestasis was observed during the 
remaining 24-month observation period.8 In a review of 16 
studies by Scheffer et al, bile duct complications after hepatic 
IRE were reported in 6 (4.8%) of 129 cases.9 Dollinger et al 
observed biliary structures for the first 3 days and laboratory 
levels (alkaline phosphatase and serum bilirubin) for 1–2 
months after IRE and detected 15 alterations (27.3%; 
Table 5 Results of Binary Logistic Regression Model Predicting Biliary Alterations
Variable OR (95% CI) P value
Age: <65y vs ≥65y 3.76 (0.83–17.04) 0.086
Sex: female vs male 1.24 (0.25–6.16) 0.794
Nature of bile ducts: minor vs major 2.70 (0.32–22.69) 0.360
Liver cirrhosis 5.83 (0.93–36.70) 0.060
Number of IRE electrodes: ≤4 vs >4 1.35 (0.27–6.84) 0.719
Bile duct location: abutting or distant vs encased 1.01 (0.20–5.07) 0.987
Tumor type: primary vs secondary hepatic malignancy 6.15 (0.84–44.84) 0.073
Ablation volume: ≤60 mL vs >60 mL 0.74 (0.20–2.74) 0.648
Presence of hepatic stents or metallic implants 0.59 (0.15–2.39) 0.460
Distance needle to bile duct: ≤0.3 cm vs >0.3 cm 0.70 (0.19–2.61) 0.592
Abbreviations: IRE, irreversible electroporation; OR, odds ratio; CI, confidence interval.
Table 6 Results of Binary Logistic Regression Model Predicting 
Postinterventional Elevated Values of Alkaline Phosphatase or 
Serum Bilirubin
Variable OR (95% CI) P value
Ablation volume: ≤60 mL vs >60 mL 0.19 (0.32–1.08) 0.061
Tumor volume: ≤1.8 mL vs >1.8 mL 2.36 (0.52–10.63) 0.264
Abbreviations: IRE, irreversible electroporation; OR, odds ratio; CI, confidence 
interval.
Table 7 Evolution of Laboratory Values During the First 3 Months After IRE in 53 Ablation Procedures
Preinterventional Day 1–3 6 Weeks 3 Months
Normal Increased Normal Increased Normal Increased Normal Increased
Bilirubin 46 7 22 31 38 15 43 10
Alkaline phosphatase 38 15 33 20 30 23 34 19
Notes: Standard value of alkaline phosphatase: 45–117 U/L; Standard value of bilirubin: 0.2–1.0 mg/dL. 
Abbreviation: IRE, irreversible electroporation.
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narrowing: n=8; dilatation: n=7) in 55 bile ducts (24 patients) 
1–3 days after IRE of 53 hepatic tumors. All of the 55 bile 
ducts were located ≤1.0 cm from the ablation zone. The 
authors also reported one case of long-term increased labora-
tory levels (alkaline phosphatase), which were presumed to 
be caused by local tumor recurrence.10
Most of these previous studies do not include any, or at 
most a short-term follow-up control of the evaluated para-
meters. Consequently, a potential biliary alteration occurring 
for the first time at one of the later follow-up controls could 
not have been detected. Furthermore, the evolution of the 
observed parameters cannot be evaluated. Some of the stu-
dies that included a follow-up control present some limita-
tions because there was no exactly predefined follow-up 
schedule for the time of data acquisition or because of 
significant lack of data during the follow-up. The aim of 
the current study was to evaluate potential biliary alterations 
and changes of alkaline phosphatase and serum bilirubin 
levels after IRE at predefined points of time to investigate 
an exact evolution during the whole follow-up period.
Narrowing of the bile duct can constitute a potential 
complication of IRE, which has already been observed in 
an animal study by Choi et al, who reported seven cases of 
bile duct narrowing during the first 8 weeks after 12 IRE 
procedures of swine liver.11 In our trial, bile duct narrowing 
(Figure 1) represented the most frequently observed biliary 
alteration (n=22) of all 38 alterations, which coincided with 
the findings of Dollinger et al, who observed bile duct 
narrowing in 53.3% of all complications.10 Six (27.3%) of 
all cases of bile duct narrowing were observed for the first 
time 6 weeks (n=3) and 3 months (n=3) after IRE (Table 3). 
In 10 cases, bile duct narrowing had resolved 6 weeks after 
the intervention, whereas in 12 (54.5%) of all 22 cases, it 
persisted until the 3-month follow-up control. Bile duct 
narrowing can occur as a result of edematous alterations in 
the ablated tissue and the adjacent intact liver parenchyma, 
as reported in several studies.3,12 Moreover, although IRE is 
believed to be a primarily nonthermal technique, there are 
some reports of heat development adjacent to the 
electrodes,13 which could potentially cause thermal coagula-
tion and stenosis of a bile duct that was directly in contact 
with one of the IRE-electrodes.4 The present study indicated 
that bile duct narrowing is not only a typical early complica-
tion of IRE but also persists during the course of the post-
ablative period.
In contrast to the results of Ueshima et al, who per-
formed endoscopy-guided intraluminal IRE in the com-
mon bile duct of six pigs without the occurrence of 
ensuing bile duct dilatation during the first postinterven-
tional week,14 in our trial bile duct dilatation represented 
14 of all 38 biliary alterations (Figure 2). Consequently, it 
constituted the second most common biliary alteration, 
similar to the observations made by Dollinger et al10 10 
had resolved 6 weeks (n=9) or 3 months (n=1) after IRE, 
whereas 4 (28.6%) of all 14 dilatations were still present at 
the last follow-up control. The findings suggest that bile 
duct dilatation, similar to bile duct narrowing, does not 
solely represent an early complication of IRE. Reactive 
choledochitis is presumed to be a potential cause of bile 
duct dilatation, as reported in a preliminary animal study.7 
Figure 1 An 80-year-old woman with a centrally located HCC. (A) Coronal contrast-enhanced T1 vibe 3d fat-suppressed magnetic resonance imaging, conducted 
preinterventionally during the hepatobiliary phase, shows a centrally located HCC (white arrow) and a left major bile duct without any relevant narrowing (red arrow). (B) 
One day after IRE, coronal contrast-enhanced T1 vibe 3d fat-suppressed magnetic resonance imaging, conducted during the hepatobiliary phase, shows a hypointense 
ablation defect (white arrow) and a newly occurred narrowing of the left major bile duct (red arrow).
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Although it has been proposed as a possible reason for bile 
duct narrowing,3,12 peridochal edema is also assumed to 
cause dilatation of bile ducts adjacent to the ablation 
zone.7 In the current study, bilomas were a rarely occur-
ring biliary complication (Table 3). All bilomas (n=2) 
were caused by IRE itself and had resolved 6 weeks 
after IRE without the need for additional treatment such 
as abdominal draining. In contrast to the occurrence of 
narrowing and dilatation of the bile duct, the findings 
suggested that bilomas seem to be an early complication 
of IRE. Regarding the time of the first occurrence of all 
biliary alterations, the results indicate that only bile duct 
narrowing represented a delayed alteration being detected 
for the first time 6 weeks (n=3) and 3 months (n=3) after 
IRE. Especially 3 months after the intervention it has to be 
discussed whether these alterations can be solely inter-
preted as a delayed complication of IRE or if there are 
other potential reasons such recurrent cholangitis or a prior 
treatment by another kind of therapy, eg radiotherapy.
None of the observed biliary alterations after IRE 
required an additional intervention or were classified as 
“severe” or “life-threatening”. They all belonged to the 
same category “asymptomatic or mild symptoms; clinical 
or diagnostic observations only; intervention not indicated” 
and were consequently categorized “grade 1” based on 
CTCAE Version 5.0.5 Regarding preclinical animal studies 
evaluating blood chemistry after hepatic IRE in pigs, the 
literature offers diverse findings. Choi et al could not detect 
elevated levels of serum bilirubin and alkaline phosphatase 
during the first 8 weeks after the intervention,11 whereas 
Charpentier et al reported a temporary elevation of serum 
bilirubin 5 days after IRE, which had normalized by post- 
ablation day 14.15 In comparison, in human studies small 
increases in the levels of alkaline phosphatase and serum 
bilirubin are commonly observed in the first few days after 
IRE and are probably caused by several factors. Silk et al 
assumed stasis in bile ducts originated owing to edematous 
alterations.4 One to three days after IRE, the alkaline phos-
phatase level was abnormal in 20 of 53 cases (37.7%; pre- 
existent before IRE: n=15, 28.3%). Six weeks and 3 months 
after the intervention, an increased level of alkaline phos-
phatase was observed in 23 (43.4%) and 19 (35.8%) 
patients, respectively. These findings were in accordance 
with the results of Froud et al, who ascertained a slow 
increase in alkaline phosphatase levels with a maximum 
level approximately 1 month after IRE and a prolonged 
resolution during the course of observation.16 During the 
first follow-up control, 31 of 53 cases (58.5%; pre-existent 
before IRE: n=7, 13.2%) showed elevated levels of serum 
bilirubin. 6 weeks and 3 months after IRE, abnormal levels 
of serum bilirubin were observed in 15 (28.3%) and 10 
(18.9%) patients, respectively (Table 7). These outcomes 
were partially consistent with the observations of Froud 
et al, who described two different patterns of evolution of 
serum bilirubin after IRE, of which one was an early 
increase combined with a slow resolution, whereas the 
rest of the study population showed an early peak of 
serum bilirubin followed by a rapid decrease.16
Figure 2 A 67-year-old man with a centrally located HCC. (A) Axial contrast-enhanced T1 vibe 3d fat-suppressed magnetic resonance imaging, conducted preinterven-
tionally during the hepatobiliary phase, shows a centrally located HCC (white arrow) and a major bile duct without any dilatation (red arrow). (B) One day after IRE, axial 
contrast-enhanced T1 vibe 3d fat-suppressed magnetic resonance imaging, conducted during the hepatobiliary phase, shows a slightly grown, hypointense ablation defect 
(white arrow) and a newly occurred mild dilatation of the major bile duct (red arrow).
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The current results of the binary logistic regression mod-
els suggest that the occurrence of postinterventional biliary 
alterations does not increase the risk of suffering from ele-
vated postablative levels of alkaline phosphatase (p= 0.978) 
or serum bilirubin (p= 0.943). Contrary to the findings of 
Dollinger et al,10 post-IRE vessel alterations did not occur 
significantly more frequently in patients older than 64 years 
(p=0.086). The sex of the patient, nature of bile ducts (minor 
vs major), presence of liver cirrhosis, number of IRE electro-
des (≤4 vs >4) and bile duct location (abutting or distant vs 
encased) did not show any significant relation to bile duct 
injury, which was consistent with the results of Dollinger 
et al.10 The characteristics “tumor type (primary vs second-
ary hepatic malignancy)”, “ablation volume (≤60 mL vs 
>60 mL)”, “the presence of hepatic stents or metallic 
implants” and “the relative distance from needle to bile 
duct (≤0.3 cm vs >0.3 cm)”, which were not evaluated in 
the binary logistic regression model of Dollinger et al,10 also 
did not show any significant influence on bile duct injury.
The current study has several limitations: The first one is 
the retrospective nature of the study. Moreover, the study 
group consisted of a heterogeneous patient population with 
regard to sex and tumor type. Furthermore, a lot of patients had 
undergone an additional tumor treatment, such as chemother-
apy or radiotherapy, which could have had a damaging effect 
on the observed bile ducts or caused changes in alkaline 
phosphatase or serum bilirubin levels. Additionally, there 
was no evaluation of data concerning existing biliary sludge 
or stones. Because it is not known whether these factors could 
influence post-IRE bile duct alterations, the lack of these data 
is another limitation of the present study.
Conclusions
Bile ducts located in proximity to the ablation zone are 
usually affected by several alterations, of which dilatation 
and especially narrowing of the bile duct commonly repre-
sent a long-term complication after IRE. Furthermore, 
a definite correlation between the frequently observed 
prolonged post-ablative elevation of alkaline phosphatase 
and serum bilirubin levels and the postinterventional bili-
ary alterations could not be proven.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines 
for radiofrequency ablation of liver tumors. Cardiovasc Intervent 
Radiol. 2010;33(1):11–17. doi:10.1007/s00270-009-9736-y
2. Ahmed M. Technology Assessment Committee of the Society of 
Interventional Radiology. Image-guided tumor ablation: standardiza-
tion of terminology and reporting criteria-a 10-year update: supple-
ment to the consensus document. J Vasc Interv Radiol. 2014;25 
(11):1706–1708. doi:10.1016/j.jvir.2014.09.005
3. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new 
ablation modality - clinical implications. Technol Cancer Res Treat. 
2007;6(1):37–48. doi:10.1177/153303460700600106
4. Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peri-
biliary tumors with irreversible electroporation. J Vasc Interv Radiol. 
2014;25(1):112–118. doi:10.1016/j.jvir.2013.10.012
5. U.S. Department of Health and Human Services. Common 
Terminology Criteria for Adverse Events (CTCAE). Version 5.0; 
November 27, 2017. Available from: https://ctep.cancer.gov/protocol 
development/electronic_applications/docs/CTCAE_v5_Quick_ 
Reference_5x7.pdf. Accessed September 5, 2020.
6. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. 
Semin Oncol. 2002;29(2):107–118. doi:10.1053/sonc.2002.31676
7. Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible 
electroporation: ultrasound and immunohistological correlation. 
Technol Cancer Res Treat. 2007;6(4):287–294. doi:10.1177/ 
153303460700600404
8. Distelmaier M, Barabasch A, Heil P, et al. Midterm safety and 
efficacy of irreversible electroporation of malignant liver tumors 
located close to major portal or hepatic veins. Radiology. 2017;285 
(3):1023–1031.
9. Scheffer HJ, Nielsen K, de Jong MC, et al. Irreversible electropora-
tion for nonthermal tumor ablation in the clinical setting: a systematic 
review of safety and efficacy. J Vasc Interv Radiol. 2014;25 
(7):997–1011. doi:10.1016/j.jvir.2014.01.028
10. Dollinger M, Zeman F, Niessen C, et al. Bile duct injury after 
irreversible electroporation of hepatic malignancies: evaluation of 
MR imaging findings and laboratory values. J Vasc Interv Radiol. 
2016;27(1):96–103. doi:10.1016/j.jvir.2015.10.002
11. Choi JW, Lu DSK, Osuagwu F, Raman S, Lassman C. Assessment of 
chronological effects of irreversible electroporation on hilar bile 
ducts in a porcine model. Cardiovasc Intervent Radiol. 2014;37 
(1):224–230. doi:10.1007/s00270-013-0731-y
12. Lee YJ, Lu DS, Osuagwu F, Lassman C. Irreversible electropora-
tion in porcine liver: acute computed tomography appearance 
of ablation zone with histopathologic correlation. 
J Comput Assist Tomogr. 2013;37(2):154–158. doi:10.1097/ 
RCT.0b013e31827dbf9b
13. Faroja M, Ahmed M, Appelbaum L, et al. Irreversible electroporation 
ablation: is all the damage nonthermal? Radiology. 
2012;266:462–470. doi:10.1148/radiol.12120609
14. Ueshima E, Schattner M, Mendelsohn R, et al. Transmural ablation 
of the normal porcine common bile duct with catheter-directed irre-
versible electroporation is feasible and does not impact duct patency. 
Gastrointest Endosc. 2018;87(1):300.e1–300.e6. doi:10.1016/j. 
gie.2017.05.004
15. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. 
Irreversible electroporation of the liver and liver hilum in swine. 
HPB. 2011;13(3):168–173. doi:10.1111/j.1477-2574.2010.00261.x
16. Froud T, Venkat SR, Barbery KJ, Gunjan A, Narayanan G. Liver 
function tests following irreversible electroporation of liver tumors: 
experience in 174 procedures. Tech Vasc Interv Radiol. 2015;18 
(3):140–146. doi:10.1053/j.tvir.2015.06.004
Bäumler et al                                                                                                                                                         Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                             



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Cancer Management and Research                                                                                                   Dovepress 
Publish your work in this journal 
Cancer Management and Research is an international, peer-reviewed 
open access journal focusing on cancer research and the optimal use of 
preventative and integrated treatment interventions to achieve improved 
outcomes, enhanced survival and quality of life for the cancer patient. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.  
Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal
Dovepress                                                                                                                                                         Bäumler et al
Cancer Management and Research 2020:12                                                                               submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
